Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Aug 3;16(8):e0255646. doi: 10.1371/journal.pone.0255646

Seasonal influenza during the COVID-19 pandemic in Bangladesh

Zubair Akhtar 1,*, Fahmida Chowdhury 1, Mahmudur Rahman 1, Probir Kumar Ghosh 1, Md Kaousar Ahmmed 1, Md Ariful Islam 1, Joshua A Mott 2, William Davis 2
Editor: Muhammad Adrish3
PMCID: PMC8330950  PMID: 34343203

Abstract

Introduction

During the 2019 novel coronavirus infectious disease (COVID-19) pandemic in 2020, limited data from several countries suggested reduced seasonal influenza viruses’ circulation. This was due to community mitigation measures implemented to control the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used sentinel surveillance data to identify changes in the 2020 influenza season compared with previous seasons in Bangladesh.

Methods

We used hospital-based influenza surveillance (HBIS) data of Bangladesh that are generated year-round and are population-representative severe acute respiratory infection (SARI) data for all age groups from seven public and two private tertiary care level hospitals data from 2016 to 2019. We applied the moving epidemic method (MEM) by using R language (v4.0.3), and MEM web applications (v2.14) on influenza-positive rates of SARI cases collected weekly to estimate an average seasonal influenza curve and establish epidemic thresholds.

Results

The 2016–2019 average season started on epi week 18 (95% CI: 15–25) and lasted 12.5 weeks (95% CI: 12–14 weeks) until week 30.5. The 2020 influenza season started on epi week 36 and ended at epi week 41, lasting for only five weeks. Therefore, influenza epidemic started 18 weeks later, was 7.5 weeks shorter, and was less intense than the average epidemic of the four previous years. The 2020 influenza season started on the same week when COVID-19 control measures were halted, and 13 weeks after the measures were relaxed.

Conclusion

Our findings suggest that seasonal influenza circulation in Bangladesh was delayed and less intense in 2020 than in previous years. Community mitigation measures may have contributed to this reduction of seasonal influenza transmission. These findings contribute to a limited but growing body of evidence that influenza seasons were altered globally in 2020.

Introduction

In early 2020, the United States and several Asian countries [14] in the Northern Hemisphere reported sharp declines in the numbers of cases of seasonal influenza, which typically occurs during the months of October to April in these countries. In the Southern Hemisphere, Australia, Chile, South Africa and New Zealand reported similar observations during influenza season, which occurs typically from April to September in these countries [57]. Previous studies suggested that the decline in seasonal influenza virus activity may have been attributed to widespread community mitigation measures implemented to control the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 5, 7]. Further exploration of influenza seasonality in the context of SARS-CoV-2 interventions may improve our understanding of how these interventions may impact seasonal influenza transmission.

Bangladesh is a tropical country in the Northern Hemisphere, and its annual seasonal influenza epidemic occurs typically during the monsoon period, from May to September, which reflects a Southern Hemisphere pattern [8]. The SARS-CoV-2 virus emerged in Bangladesh on epidemiologic (epi) week 11 of 2020 (March 08, 2020), and pandemic control measures were initiated on March 16, 2020 (epi week 12) through closing all educational institutes and on March 26, 2020 (epi week 13) through suspending all political, religious, social, and cultural gathering including state public programs and events; closure of transport services including domestic and international flights, and closure of all public and private offices except for hospitals, kitchen markets, drug stores, and emergency services [9]. Social distancing, wearing face masks and maintaining hand hygiene were made mandatory after May 30, 2020 (from epi week 23) [10]. Enforcement of some measures was relaxed after May 30, 2020 (from epi week 23) at which time public transport service resumed (ground and air) and shopping malls/service sectors opened on a limited scale [10]. All control measures were enforced up to August 31, 2020 (epi week 36) [11].

We used sentinel surveillance data to identify changes in the 2020 influenza season compared with previous seasons in Bangladesh.

Methods

The hospital-based influenza surveillance (HBIS) system in Bangladesh generates year-round population-representative data for all age groups from seven public and two private tertiary care level hospitals through a collaboration between the Institute of Epidemiology, Disease Control and Research (IEDCR) of the Government of Bangladesh, the International Centre for Diarrheal Diseases Research, Bangladesh (icddr,b) and the United States Centers for Disease Control and Prevention (US CDC) [12]. Participating hospitals were:

Public hospitals
1 Rajshahi Medical College Hospital, Rajshahi
2 Cumilla Medical College Hospital, Cumilla
3 Khulna Medical College Hospital, Khulna
4 Sher-e-Bangla Medical College Hospital, Barishal
5 Chattogram Medical College Hospital, Chattogram
6 M Abdur Rahim Medical College Hospital, Dinajpur
7 Jashore 250 bed General Hospital, Jashore
Private hospitals
8 Jahurul Islam Medical College Hospital, Kishoregonj
9 Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet

This surveillance system has been described elsewhere, and outputs of the system include the number of Severe Acute Respiratory Infection (SARI) cases (defined as: history of fever or measured fever ≥38C with cough, onset within the previous 10 days, and requiring hospitalization) each week and the percent of those cases that tested positive for influenza viruses using real-time reverse transcription polymerase chain reaction (rRT- PCR) [12, 13]. The hospital-based influenza surveillance protocol in Bangladesh was reviewed and approved by the IRB at icddr,b. In addition, the CDC’s Human Research Protection Office has reviewed and approved a continuing reliance on the icddr,b IRB.§ Participants or legal guardians provided written, informed consent before data and biological sample collection and fully anonymized data were accessed for analysis

We used the R language (v4.0.3) and MEM web applications (v2.14) to generate an average influenza seasonal curve using influenza positive rates of SARI cases collected weekly by the HBIS from January 2016 to December 2019 [14]. Briefly, this software generated epidemic curves of percent of SARI cases positive for influenza for each season of surveillance data from Bangladesh from 2016–2019. The MEM program then aligned the curves to generate an average curve, and set thresholds to define pre-epidemic, epidemic, and post-epidemic periods, as well as medium, high, and very high intensity thresholds for seasonal influenza activity [14, 15]. To determine the epidemic threshold, the MEM software calculates the upper limit of a 95% confidence interval around the 30 highest weekly values before the epidemic period, and intensity thresholds are calculated so that approximately 60% of seasons will cross the medium intensity threshold, 10% will cross the high threshold, and 2.5% will cross the very high threshold. The model estimates sensitivity (correctly defining the epidemic period above the epidemic threshold) and specificity (correctly defining the non-epidemic period below the epidemic threshold) of the model, and it calculates 95% confidence intervals for the average season’s start date and duration [14]. We applied the average seasonal thresholds to identify the beginning, end, and intensity of the 2020 influenza season.

Results

From 2016 to 2019, the HBIS reported 2,714 to 5,001 SARI cases per year; 15% to 26% of these were influenza positive. The HBIS included cases for each month of 2020, although the total of 2,361 was less than in previous years, with an average of 8% influenza positive over the entire year (Fig 1).

Fig 1. SARI cases and influenza infection detected through hospital-based influenza surveillance in Bangladesh, 2016–2020.

Fig 1

The MEM software generated seasonal influenza epidemic curves for 2016–2020 (Fig 2) and an average curve for 2016–2019 seasons (Fig 3). Based on the average curve, MEM identified thresholds for the start of seasonal influenza season (21% of SARI cases influenza positive), the end of the season (27% positive), and seasonal intensity (medium: 47%, high: 60%, very high: 67% positive) (Figs 1 and 2). The sensitivity of this model was 78% with 96% specificity; that is, for each season used to build the model (2016–2019), 78% of the weeks above the epidemic threshold fell within the model’s predicted epidemic season and 96% of the weeks below the epidemic threshold fell within the model’s predicted non-epidemic season.

Fig 2. Time series of influenza epidemic, the epidemic periods modelled by MEM for season 2016–2020 in Bangladesh.

Fig 2

Fig 3. Average epidemic curve and thresholds, levels of intensity and modelled influenza season 2016–2019 in Bangladesh.

Fig 3

The 2019 season was the most intense (peak 72% positivity), while the 2016 and 2018 seasons exceeded the high intensity threshold (peaks at 61 and 65% positivity, respectively). The 2017 season exceeded the medium intensity threshold (peak at 57% positivity), and the 2020 season exceeded the “season start” threshold but did not reach the medium intensity threshold (peak at 43% positivity, Fig 2). The 2016–2019 seasons started on weeks 21, 27, 30 and 23 respectively, and the average season started on epi week 18 (95% CI: 15–25) and lasted 12.5 weeks (95% CI: 12–14 weeks), until week 30.5 (Figs 2 and 3). The 2020 influenza season started on epi week 36 (at baseline epidemic threshold 21%) and ended at epi week 41 (at post epidemic threshold 27%), thus lasting for only 5 weeks (Fig 4). The 2020 influenza season started on the same week COVID-19 control measures were halted, and 13 weeks after the measures were relaxed.

Fig 4. Epidemic threshold, levels of intensity and modelled influenza season 2020 in Bangladesh.

Fig 4

Discussion

Bangladesh maintained influenza surveillance throughout 2020. Data indicated that the start of the 2020 influenza epidemic was 18 weeks delayed compared with the four previous seasons’ average, and it lasted less than half (5 weeks vs. 12.5 weeks) the duration of previous seasons. Similar marked reductions in influenza circulation were also reported in Singapore, Thailand, China, Taiwan, Australia, South Africa, and Chile during the COVID-19 pandemic; these reports cited a collateral effect of pandemic control measures as a potential cause [16].

The start of the 2020 influenza season began after most of SARS-CoV-2 mitigation interventions ended. Public health control efforts undertaken to control the COVID-19 pandemic in Bangladesh were initiated five weeks before the average start of the previous four years’ influenza seasons and may have contributed to delaying the country’s 2020 seasonal influenza epidemic. Pandemic control measures were ultimately enforced until epi week 36 but after epi week 23 they were relaxed [11]. The 2020 influenza season started on epi week 36. Since both SARS-CoV-2 and influenza viruses have similar modes of transmission through contact, droplet, and airborne routes [16], pandemic control efforts may have also limited the transmission of influenza virus, a less transmissible virus, during its peak season in Bangladesh. Therefore, it is likely that efforts to mitigate SARS-CoV-2 contributed to the delay of the 2020 influenza season in Bangladesh.

Strengths of this report include use of data from a robust surveillance system that continued throughout the COVID-19 pandemic in 2020, and the use of an established modeling method to generate seasonal influenza epidemic timing and thresholds [7]. An important limitation is the 42% lower number of SARI cases detected by surveillance in 2020, compared with the average of the four previous seasons. This decline may have resulted from reduced health-seeking behaviors, undocumented changes in sampling of SARI patients, limited availability of personal protective equipment and reagents for sampling and testing, and logistic challenges of surveillance operations. All of these challenges may have been associated with the SARS-CoV-2 pandemic and contributed to fewer SARI patients presenting and tested for influenza and decreased the precision of relationship with influenza. Furthermore, the data presented here includes only hospital-based surveillance. Less severe influenza cases—those that did not require hospitalization—were not considered in this analysis and it is possible that trends in inpatient hospital admissions or health seeking behaviour may have changed due to the COVID-19 pandemic and confounded the influenza positivity rates. Another limitation is that we only used four seasons of data to generate the average epidemic curve; given considerable variability in influenza seasonality, more data would yield more precise start and end dates of the average season.

In conclusion, our findings suggest that seasonal influenza circulation in Bangladesh was delayed and less intense in 2020, compared with previous years. Community mitigation measures may have contributed to this reduction of seasonal influenza transmission.

Data Availability

According to institutional data policy of the icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), only summary of data can be publicly displayed or can be made publicly accessible. To protect intellectual property rights of primary data, icddr,b cannot make primary data publicly available. However, upon request, Institutional Data Access Committee of icddr,b can provide access to primary data to any individual, upon reviewing the nature and potential use of the data. Requests for data can be forwarded to: Ms. Armana Ahmed, Head, Research Administration, icddr,b, Dhaka, Bangladesh, Email: aahmed@icddrb.org, Phone: +88 02 9827001-10 (ext. 3200).

Funding Statement

This hospital-based influenza surveillance was funded by the Influenza Division of Centers for Disease Control and Prevention (CDC), Atlanta, under the co-operative agreement (6 NU51IP000852-05-01). icddr,b is grateful to the Governments of Bangladesh, Canada, Sweden, and the UK for providing core/unrestricted support. The funders had no conflict of interest with the contents of the manuscript.

References

  • 1.Soo RJJ, Chiew CJ, Ma S, Pung R, Lee V. Decreased influenza incidence under COVID-19 control measures, Singapore. Emerging infectious diseases. 2020;26(8):1933. doi: 10.3201/eid2608.201229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Suntronwong N, Thongpan I, Chuchaona W, Budi Lestari F, Vichaiwattana P, Yorsaeng R, et al. Impact of COVID-19 public health interventions on influenza incidence in Thailand. Pathogens and Global Health. 2020:1–3. doi: 10.1080/20477724.2020.1777803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lei H, Xu M, Wang X, Xie Y, Du X, Chen T, et al. Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China. The Journal of infectious diseases. 2020;222(11):1780–3. doi: 10.1093/infdis/jiaa570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kuo S-C, Shih S-M, Chien L-H, Hsiung CA. Collateral benefit of COVID-19 control measures on influenza activity, Taiwan. Emerging infectious diseases. 2020;26(8):1928. doi: 10.3201/eid2608.201192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased influenza activity during the covid-19 pandemic—United States, Australia, Chile, and South Africa, 2020. Morbidity and Mortality Weekly Report. 2020;69(37):1305. doi: 10.15585/mmwr.mm6937a6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sullivan SG, Carlson S, Cheng AC, Chilver MB, Dwyer DE, Irwin M, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Eurosurveillance. 2020;25(47):2001847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nature communications. 2021;12(1):1–7. doi: 10.1038/s41467-020-20314-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Zaman R, Alamgir ASM, Rahman M, Azziz-Baumgartner E, Gurley E, Sharker Y, et al. Influenza in Outpatient ILI Case-Patients in National Hospital-Based Surveillance, Bangladesh, 2007–2008. PloS one. 2009;4:e8452. doi: 10.1371/journal.pone.0008452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Organization WH. Coronavirus disease (COVID-2019) Bangladesh situation report # 4 2020. [updated 24-03-2020. Available from: https://www.who.int/docs/default-source/searo/bangladesh/covid-19-who-bangladesh-situation-reports/who-ban-covid-19-sitrep-04.pdf?sfvrsn=69b6d931_8. [Google Scholar]
  • 10.Organization WH. Coronavirus disease (COVID-2019) Bangladesh situation report # 14 2020. [updated 01-06-2020. Available from: https://www.who.int/docs/default-source/searo/bangladesh/covid-19-who-bangladesh-situation-reports/who-ban-covid-19-sitrep-14-20200601.pdf?sfvrsn=657b0f1b_4. [Google Scholar]
  • 11.Organization WH. WHO COVID-19 case definition. World Health Organization; 2020. [Google Scholar]
  • 12.Zaman RU, Alamgir A, Rahman M, Azziz-Baumgartner E, Gurley ES, Sharker MAY, et al. Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007–2008. PloS one. 2009;4(12):e8452. doi: 10.1371/journal.pone.0008452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ahmed M, Aleem MA, Roguski K, Abedin J, Islam A, Alam KF, et al. Estimates of seasonal influenza‐associated mortality in Bangladesh, 2010‐2012. Influenza and other respiratory viruses. 2018;12(1):65–71. doi: 10.1111/irv.12490 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vega T, Lozano JE, Meerhoff T, Snacken R, Mott J, Ortiz de Lejarazu R, et al. Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method. Influenza and other respiratory viruses. 2013;7(4):546–58. doi: 10.1111/j.1750-2659.2012.00422.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Vega T, Lozano JE, Meerhoff T, Snacken R, Beauté J, Jorgensen P, et al. Influenza surveillance in E urope: comparing intensity levels calculated using the moving epidemic method. Influenza and other respiratory viruses. 2015;9(5):234–46. doi: 10.1111/irv.12330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, et al. SARS-CoV-2 and influenza virus co-infection. Lancet (London, England). 2020;395(10236):e84. doi: 10.1016/S0140-6736(20)31052-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Muhammad Adrish

25 May 2021

PONE-D-21-10066

Seasonal influenza during the COVID-19 pandemic in Bangladesh

PLOS ONE

Dear Dr. Akhtar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please see comments made by reviewers and provide point by point response in your revised manuscript

==============================

Please submit your revised manuscript by June 22nd 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2)  Please include in your Methods section (or in Supplementary Information files) the participating hospitals/institutions.

3) In the Methods section and the online ethics statement, please provide clarification whether the current study reported required ethical oversight. Furthermore, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a well written and timely report detailing reduced hospitalizations due to seasonal influenza during the COVID-19 pandemic in Bangladesh. The results are consistent with reports from other countries, and represent a valuable addition to this expanding literature. I have only one minor comment and suggestion for improvement. Since this study relied on data from a hospital based influenza surveillance system, it necessarily does not capture non-hospitalized influenza infections. Therefore, the epidemiologic picture of seasonal influenza presented is limited, and could be affected by unmeasured confounding variables, such as reduced diagnosis or hospitalization rates for severe influenza disease due to redirected public health resources. While this limitation does not invalidate this report, it should be discussed as a limitation in the Discussion section of the manuscript.

Reviewer #2: The study was considered not so satisfied in results which might be further explored and explained.

And when it comes to the question whether a statistical model could be applied to actual disease outbreak alarming, more data would be needed to do modeling.

Reviewer #3: The authors studied the changes in influenza epidemic patterns in Bangladesh during COVID-19 pandemic using hospital-based influenza surveillance data of Bangladesh from 2016-2020 and reported that 2020 influenza season was delayed and less intense than the previous years. I have some questions about data analysis.

How is the average curve calculated? Was a function in the R mem package used to align the curves of seasons 2016-2019 to generate the average curve? Why were the average seasonal thresholds of 2016-2019 used to identify the beginning, ending and intensity of 2020 influenza season instead of letting the data from 2020 determine the thresholds.

Please give the MEM results (refer to tables in references 14, 15) for each season separately.

Why is the last black point (2020 around weeks 40-45, y-axis is round 0.18) in Figure 2 black (epidemic) instead of blue (post-epidemic) since it is already lower than the post-threshold. Also shouldn’t the start of the epidemic be the first week where the rate is higher than pre-threshold? The black points or blue point (Figure 3) seem to start before the rate reaches pre-epidemic threshold.

Last sentence on pages 10-11: “MEM software defines the beginning and end of the epidemic periods as the times at which the rate of positive cases is higher than optimized seasonal data, ..” shouldn’t “optimizes seasonal data” be “pre-epidemic threshold”?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Aug 3;16(8):e0255646. doi: 10.1371/journal.pone.0255646.r002

Author response to Decision Letter 0


6 Jun 2021

Reviewer 1 comment

This is a well written and timely report detailing reduced hospitalizations due to seasonal influenza during the COVID-19 pandemic in Bangladesh. The results are consistent with reports from other countries, and represent a valuable addition to this expanding literature. I have only one minor comment and suggestion for improvement. Since this study relied on data from a hospital based influenza surveillance system, it necessarily does not capture non-hospitalized influenza infections. Therefore, the epidemiologic picture of seasonal influenza presented is limited, and could be affected by unmeasured confounding variables, such as reduced diagnosis or hospitalization rates for severe influenza disease due to redirected public health resources. While this limitation does not invalidate this report, it should be discussed as a limitation in the Discussion section of the manuscript.

Response: Thank you for your appreciating and thoughtful comment about a significant limitation. We agree that the less severe cases not requiring hospitalization and redirected health resources may have influenced our results but did not invalidate our findings. Thus we have added another limitation addressing this in our discussion section as following:

“Furthermore, the data presented here includes only hospital-based surveillance. Less severe influenza cases-- those that did not require hospitalization-- were not considered in this analysis and it is possible that trends in inpatient hospital admissions or health seeking behaviour may have changed due to the COVID-19 pandemic and confounded the influenza positivity rates.”

Reviewer 2 comment

The study was considered not so satisfied in results which might be further explored and explained. And when it comes to the question whether a statistical model could be applied to actual disease outbreak alarming, more data would be needed to do modeling

Response: We thank the reviewer for this thoughtful critique of the statistical model. Since we are describing the influenza season of 2020 only, we restricted our analysis to the previous four years because the MEM model achieved a sensitivity of 78% with 96% specificity. These sensitivity and specificity were above the limits of a robust model as cross-validated in previous literature (reference #14 in manuscript, Vega, 2013). We agree with the reviewer that when this model would be applied for actual forecasting, more data would yield a more precise start of an epidemic. If we had used this model to predict future influenza outbreaks in a paper, e.g., that of 2021, we would have certainly opted to use more data.

Reviewer 3 comments

The authors studied the changes in influenza epidemic patterns in Bangladesh during COVID-19 pandemic using hospital-based influenza surveillance data of Bangladesh from 2016-2020 and reported that 2020 influenza season was delayed and less intense than the previous years. I have some questions about data analysis.

1. How is the average curve calculated? Was a function in the R mem package used to align the curves of seasons 2016-2019 to generate the average curve? Why were the average seasonal thresholds of 2016-2019 used to identify the beginning, ending and intensity of 2020 influenza season instead of letting the data from 2020 determine the thresholds.

Response: Thank you for seeking clarification. The function in the R MEM package generated the generated seasonal influenza epidemic curves for 2016-2020 (Figure 2). Following this, epidemic thresholds are calculated, and average thresholds based on the 2016-2019 seasons are illustrated in Figure 3. Since we are describing season 2020 relative to previous years (2016-2019), in figure 4, actual 2020 data is used to compare with threshold values set by 2016-2019 data.

2. Please give the MEM results (refer to tables in references 14, 15) for each season separately.

Response: We appreciate your interest in moving epidemic method (MEM). The tables added in reference 14 and 15 describe the MEM and have been published establishing the MEM in describing influenza seasons. Figures 2 and 3 show individual seasons and the average curve generated from these seasons’ data. We added information to the text describing start weeks and peak intensities:

“The 2019 season was the most intense (peak 72% positivity), while the 2016 and 2018 seasons exceeded the high intensity threshold (peaks at 61 and 65% positivity, respectively). The 2017 season exceeded the medium intensity threshold (peak at 57%), and the 2020 season exceeded the “season start” threshold but did not reach the medium intensity threshold (peak at 43% positivity, Fig 2). The 2016-2019 seasons started on weeks 21, 27, 30 and 23 respectively, and the average season started on epi week 18 (95% CI: 15-25) and lasted 12.5 weeks (95% CI: 12-14 weeks), until week 30.5 (Figs 2 and 3).”

3. Why is the last black point (2020 around weeks 40-45, y-axis is round 0.18) in Figure 2 black (epidemic) instead of blue (post-epidemic) since it is already lower than the post-threshold. Also shouldn't the start of the epidemic be the first week where the rate is higher than pre-threshold? The black points or blue point (Figure 3) seem to start before the rate reaches pre-epidemic threshold.

Response: We appreciate your discreet scrutiny of the figures. The curves generated in Fig 2 are based on actual data points (proportion positives) of the respective years. Here deep blue ones are pre-epidemic, black/grey ones are epidemic, and light blue/cyan is post-epidemic data points. The threshold lines generated are based on the average of the 2016-2019 seasons, and data in the 2020 season is smoothed for analysis. Because data are smoothed for analyses when points fall very close to the thresholds, the smoothing may place them in a different threshold category from where they appear to be on the graph.

4. Last sentence on pages 10-11: "MEM software defines the beginning and end of the epidemic periods as the times at which the rate of positive cases is higher than optimized seasonal data, .." shouldn't "optimizes seasonal data" be "pre-epidemic threshold"?

Response: We added some more detail to the methods, to include this, “To estimate the epidemic threshold, the MEM software calculates the upper limit of a 95% confidence interval around the 30 highest weekly values before the epidemic period,” we also added a reference to the Vega 2013 paper which describes the MEM methodology in detail.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Muhammad Adrish

21 Jul 2021

Seasonal influenza during the COVID-19 pandemic in Bangladesh

PONE-D-21-10066R1

Dear Dr. Akhtar,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All comments have been addressed.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

Acceptance letter

Muhammad Adrish

26 Jul 2021

PONE-D-21-10066R1

Seasonal influenza during the COVID-19 pandemic in Bangladesh

Dear Dr. Akhtar:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Muhammad Adrish

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    According to institutional data policy of the icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), only summary of data can be publicly displayed or can be made publicly accessible. To protect intellectual property rights of primary data, icddr,b cannot make primary data publicly available. However, upon request, Institutional Data Access Committee of icddr,b can provide access to primary data to any individual, upon reviewing the nature and potential use of the data. Requests for data can be forwarded to: Ms. Armana Ahmed, Head, Research Administration, icddr,b, Dhaka, Bangladesh, Email: aahmed@icddrb.org, Phone: +88 02 9827001-10 (ext. 3200).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES